Quick answer: BPC-157 is a 15-amino-acid synthetic peptide studied in laboratory and animal models for tissue repair, blood vessel growth and gut protection. Almost all of the published work is preclinical. Human data is very limited.
This article summarizes published research for a scientific audience. It is not medical advice and does not describe personal use.
What Is BPC-157?
- Name: Body Protection Compound-157, a pentadecapeptide (15 amino acids).
- Origin: a synthetic fragment modeled on a protein found in human gastric juice.
- Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
- Molecular weight: roughly 1,419 Da.
- Main research group: work led by Predrag Sikiric and colleagues at the University of Zagreb, Croatia, since the 1990s.
- Stability note: reported to stay stable in gastric juice, which is unusual for a peptide and is why it was first studied in digestive models.
Why Researchers Study It
BPC-157 appears in studies across very different tissues. Researchers are interested in it because one compound shows effects in tendon, muscle, gut, nerve and blood vessel models. That breadth is also a reason for caution: many findings come from the same few labs and need independent replication.
Reported Mechanisms in the Literature
No single mechanism is confirmed. Preclinical papers point to several pathways:
- Angiogenesis: studies report upregulation of VEGFR2 signaling, linked to new blood vessel formation in injury models.
- Nitric oxide (NO) system: models suggest BPC-157 interacts with NO signaling, which affects blood flow and vessel tone.
- Cell migration and survival: in tendon fibroblast cultures, researchers reported increased outgrowth, survival and migration, with involvement of the FAK-paxillin pathway.
- Growth factor expression: some studies report changes in growth hormone receptor and EGR-1 related signaling.
- Neurotransmitter systems: rodent studies report interaction with dopaminergic and serotonergic pathways.
In plain terms: the data suggests BPC-157 may act like a signal that helps injured tissue rebuild its blood supply and cell movement. This remains a hypothesis, not a settled mechanism.
What Preclinical Studies Report
1. Tendon and Ligament Models
- Rat Achilles tendon transection studies reported improved healing and tissue organization versus controls.
- Cell culture work showed effects on tendon fibroblast behavior (see mechanisms above).
2. Muscle and Bone Models
- Rodent muscle crush and transection models reported faster functional recovery.
- Bone defect and fracture models reported improved healing markers.
3. Gastrointestinal Models
- This is where research began. Rodent models of gastric ulcers, colitis and intestinal anastomosis reported protective effects.
- Findings include reduced lesion size and improved mucosal integrity in animals.
4. Nervous System Models
- Rodent nerve injury and brain injury models reported protective or recovery-related effects.
- These studies are early and mostly from a small number of groups.
5. Vascular Models
- Studies report effects on vessel growth and on recovery of blood flow after induced vessel injury in animals.
What About Human Evidence?
This is the most important section for any researcher reading the literature.
- A systematic review of the literature found that nearly all studies were preclinical, with only a very small number of human reports.
- Human reports so far are small: a retrospective knee pain case series, a small pilot study in a bladder condition, and a tiny intravenous safety pilot.
- Early clinical trial programs were announced decades ago, but full peer-reviewed results are largely not available.
- BPC-157 is not an approved drug in any major jurisdiction.
Bottom line: animal results are interesting, but they do not establish safety or effect in humans.
Limits and Open Questions
- Replication: most positive findings come from one research network.
- Species gap: rodent results often fail to translate to humans.
- Long-term safety: no robust long-term human safety data exists.
- Angiogenesis question: a compound that promotes vessel growth raises open theoretical questions that researchers have flagged and that remain unstudied in humans.
- Study design: routes, models and endpoints vary widely, so results are hard to compare.
BPC-157 vs TB-500 in the Literature
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Type | 15-amino-acid synthetic fragment | Synthetic fragment related to thymosin beta-4 |
| Origin | Modeled on a gastric juice protein | Related to a protein found in many cell types |
| Studied for | Tendon, gut, vascular, nerve models | Cell migration, wound and cardiac models |
| Evidence level | Mostly animal and lab | Mostly animal and lab |
A dedicated comparison article is planned.
Handling and Storage Notes for Lab Use
- Lyophilized (freeze-dried) peptides are typically kept cold, dry and protected from light until use.
- For step-by-step lab preparation of lyophilized peptides, see our reconstitution guide in our research blog.
- Always follow the supplier’s certificate of analysis and your institution’s lab protocols.
Frequently Asked Questions
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. It is studied in preclinical models of tissue repair, gut protection and blood vessel growth.
Is BPC-157 FDA approved?
No. BPC-157 is not an FDA-approved drug. It is sold for laboratory research use only.
What does BPC-157 research show?
Animal and cell studies report effects on tendon, muscle, gut and vascular healing models. Human evidence is very limited.
How does BPC-157 work?
The mechanism is not confirmed. Studies point to angiogenesis signaling, the nitric oxide system and cell migration pathways.
Where did BPC-157 come from?
It was developed from a sequence found in a protective protein in human gastric juice, and has been studied mainly by a research group in Zagreb, Croatia.
Is there human clinical evidence for BPC-157?
Only a few small human reports exist. Large, controlled, peer-reviewed human trials have not been published.
What is the difference between BPC-157 and TB-500?
They are different peptides with different origins. Both are studied mostly in animal and lab models.
Key Takeaways
- BPC-157 is a 15-amino-acid peptide with a large preclinical literature.
- Reported mechanisms include angiogenesis, nitric oxide signaling and cell migration.
- Human evidence is minimal and unproven.
- Independent replication is the main gap.
Browse our research-grade BPC-157 with batch-specific certificates of analysis, or check the product certificates.
Related research reading: GHK-Cu Research: Mechanism, Evidence & a Real Case Study · MOTS-C research peptide · Tesamorelin research peptide · All research articles
Research use only. Products referenced are sold strictly for in-vitro laboratory research. Not for human or veterinary use. Not approved by the FDA to diagnose, treat, cure or prevent any disease. This article summarizes published literature and does not provide medical advice or recommend any use.
